Passage Bio Analyst Ratings
Passage Bio Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/08/2023 | 977.84% | Chardan Capital | $11 → $9 | Maintains | Buy |
05/12/2023 | 977.84% | Raymond James | $10 → $9 | Maintains | Outperform |
12/15/2022 | 1217.37% | Chardan Capital | $18 → $11 | Maintains | Buy |
11/11/2022 | 1217.37% | Guggenheim | $13 → $11 | Maintains | Buy |
11/11/2022 | 498.8% | Citigroup | $7 → $5 | Maintains | Buy |
11/08/2022 | 858.08% | Canaccord Genuity | → $8 | Initiates Coverage On | → Buy |
05/17/2022 | 1097.6% | Citigroup | $15 → $10 | Maintains | Buy |
05/17/2022 | 1097.6% | Raymond James | $24 → $10 | Maintains | Outperform |
03/08/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
03/04/2022 | 2774.25% | Raymond James | $29 → $24 | Maintains | Outperform |
01/19/2022 | 618.56% | Goldman Sachs | $29 → $6 | Downgrades | Buy → Neutral |
07/01/2021 | 3373.05% | Raymond James | → $29 | Initiates Coverage On | → Outperform |
06/15/2021 | 2894.01% | BTIG | → $25 | Initiates Coverage On | → Buy |
03/08/2021 | 5289.22% | Chardan Capital | $35.5 → $45 | Maintains | Buy |
03/04/2021 | 3492.81% | Goldman Sachs | $28 → $30 | Upgrades | Neutral → Buy |
02/04/2021 | 2894.01% | Guggenheim | → $25 | Initiates Coverage On | → Buy |
01/04/2021 | 4091.62% | JP Morgan | $25 → $35 | Upgrades | Neutral → Overweight |
12/11/2020 | 3253.29% | Citigroup | → $28 | Initiates Coverage On | → Neutral |
08/14/2020 | 2894.01% | JP Morgan | → $25 | Downgrades | Overweight → Neutral |
06/25/2020 | 3253.29% | Goldman Sachs | → $28 | Downgrades | Buy → Neutral |
05/11/2020 | 3792.22% | Chardan Capital | $30 → $32.5 | Maintains | Buy |
03/25/2020 | 3492.81% | Chardan Capital | → $30 | Initiates Coverage On | → Buy |
03/24/2020 | 3133.53% | Goldman Sachs | → $27 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/08/2023 | 977.84% | 查丹资本 | 11 美元 → 9 美元 | 维护 | 购买 |
05/12/2023 | 977.84% | 雷蒙德·詹姆 | 10 美元 → 9 美元 | 维护 | 跑赢大盘 |
2022 年 12 月 15 日 | 1217.37% | 查丹资本 | 18 美元 → 11 美元 | 维护 | 购买 |
11/11/2022 | 1217.37% | 古根海姆 | 13 美元 → 11 美元 | 维护 | 购买 |
11/11/2022 | 498.8% | 花旗集团 | 7 美元 → 5 美元 | 维护 | 购买 |
2022 年 8 月 11 日 | 858.08% | Canaccord Genu | → 8 美元 | 启动覆盖开启 | → 购买 |
05/17/2022 | 1097.6% | 花旗集团 | 15 美元 → 10 美元 | 维护 | 购买 |
05/17/2022 | 1097.6% | 雷蒙德·詹姆 | 24 美元 → 10 美元 | 维护 | 跑赢大盘 |
03/08/2022 | — | 摩根大通 | 降级 | 超重 → 中性 | |
03/04/2022 | 2774.25% | 雷蒙德·詹姆 | 29 美元 → 24 美元 | 维护 | 跑赢大盘 |
2022 年 1 月 19 日 | 618.56% | 高盛 | 29 美元 → 6 美元 | 降级 | 买入 → 中性 |
07/01/2021 | 3373.05% | 雷蒙德·詹姆 | → 29 美元 | 启动覆盖开启 | → 跑赢大盘 |
06/15/2021 | 2894.01% | BTIG | → 25 美元 | 启动覆盖开启 | → 购买 |
2021 年 8 月 3 日 | 5289.22% | 查丹资本 | 35.5 美元 → 45 美元 | 维护 | 购买 |
2021 年 4 月 3 日 | 3492.81% | 高盛 | 28 美元 → 30 美元 | 升级 | 中性 → 买入 |
2021 年 4 月 2 日 | 2894.01% | 古根海姆 | → 25 美元 | 启动覆盖开启 | → 购买 |
01/04/2021 | 4091.62% | 摩根大通 | 25 美元 → 35 美元 | 升级 | 中性 → 超重 |
2020 年 11 月 12 日 | 3253.29% | 花旗集团 | → 28 美元 | 启动覆盖开启 | → 中立 |
2020 年 8 月 14 日 | 2894.01% | 摩根大通 | → 25 美元 | 降级 | 超重 → 中性 |
06/25/2020 | 3253.29% | 高盛 | → 28 美元 | 降级 | 买入 → 中性 |
05/11/2020 | 3792.22% | 查丹资本 | 30 美元 → 32.5 美元 | 维护 | 购买 |
2020 年 3 月 25 日 | 3492.81% | 查丹资本 | → 30 美元 | 启动覆盖开启 | → 购买 |
2020 年 3 月 24 日 | 3133.53% | 高盛 | → 27 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Passage Bio (PASG)?
Passage Bio(PASG)的目标价格是多少?
The latest price target for Passage Bio (NASDAQ: PASG) was reported by Chardan Capital on August 8, 2023. The analyst firm set a price target for $9.00 expecting PASG to rise to within 12 months (a possible 977.84% upside). 6 analyst firms have reported ratings in the last year.
Chardan Capital于2023年8月8日公布了Passage Bio(纳斯达克股票代码:PASG)的最新目标股价。这家分析公司将目标股价定为9.00美元,预计PASG将在12个月内升至977.84%(可能上涨977.84%)。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Passage Bio (PASG)?
分析师对Passage Bio(PASG)的最新评级是多少?
The latest analyst rating for Passage Bio (NASDAQ: PASG) was provided by Chardan Capital, and Passage Bio maintained their buy rating.
Passage Bio(纳斯达克股票代码:PASG)的最新分析师评级由Chardan Capital提供,Passage Bio维持买入评级。
When is the next analyst rating going to be posted or updated for Passage Bio (PASG)?
Passage Bio(PASG)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析师在进行了广泛的研究(包括浏览公开财务报表、与Passage Bio的高管和客户交谈以及听取财报电话会议)后得出了股票评级。大多数分析师每三个月进行一次评级,因此每家公司每年应该获得4个评级。Passage Bio的最后一次评级是在2023年8月8日提交的,因此你应该预计下一个评级将在2024年8月8日左右公布。
Is the Analyst Rating Passage Bio (PASG) correct?
分析师评级 Passage Bio (PASG) 正确吗?
While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a maintained with a price target of $11.00 to $9.00. The current price Passage Bio (PASG) is trading at is $0.84, which is out of the analyst's predicted range.
虽然评级是主观的,会发生变化,但最新的Passage Bio(PASG)评级维持不变,目标股价为11.00美元至9.00美元。Passage Bio(PASG)目前的交易价格为0.84美元,超出了分析师的预测区间。